Shareholder Alert: The Ademi Firm investigates whether Exact Sciences Corporation is obtaining a Fair Price for its Public Shareholders

Impact · against what's priced in

The acquisition of Exact Sciences by Abbott at $105 per share is the primary driver for EXAS, while the subsequent law firm investigation is a common friction point that rarely alters the deal's expected value. For FULC and WEAV, the news signals potential legal hurdles regarding their own separate transactions.

EXAS+0.50

No priced-in read yet